Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +7.77% and +27.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?